The Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA is currently recruiting a faculty position at the Assistant Professor level.
We have recently established a multidisciplinary translational theranostics program supported by the David Geffen School of Medicine. This includes preclinical studies using small animal models of prostate cancer to create and test translatable synergistic pharmacologic approaches that increase the effectiveness of radioligand therapy, and the development of a platform technology for the synthesis and target screening of small peptides for theranostics. Clinical research includes PSMA and somatostatin receptor targeted therapy studies. To support this program, we created a research facility (the Ahmanson Division) with wet and cell culture labs, a small vivarium, a small animal imaging facility, and mass spectrometry capabilities and have used this infrastructure to initiate a target and peptide ligand discovery program.
The program is now searching for a uniquely qualified expert in target discovery and peptide and /or AB ligand development.
The proposed candidate must hold a Ph.D., M.D., or M.D. / Ph.D. degree and is expected to lead the translational research program of the theranostics program. The candidate must have documented experience in leading a research team, along with a track record of preclinical and clinical research in theranostics. There is a particular interest in receptor-based radiotherapy treatments of prostate cancer. Candidates must have a publication record in preclinical and clinical imaging and therapy research commensurate with the Assistant Professor level of this position.
The Ahmanson Translational Imaging Division has well-equipped imaging probe and drug discovery labs, molecular & cell biology labs, two Siemens RDS self-shielded cyclotrons and radiochemistry facilities, preclinical PET/CT and bioluminescence imaging systems and clinical PET/CT and SPECT/CT. The Division also has well established programs and collegial relationships with the Crump Institute for Molecular Imaging, the Jonsson Comprehensive Cancer Center and the Departments of Radiology, Radiation Oncology, Urology, Medicine, and Surgery that are important to the success of the selected candidate for this position.
Candidates should submit a letter of interest and CV addressed to: Chair of the Search Committee (Theranostics), Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA via UCLA Academic Recruit (https://recruit.apo.ucla.edu/apply/JPF03573 ), and arrange to have a statement of research accomplishments and a research plan appropriate for the position, and three letters of recommendation sent to the same address. Letters of recommendation should address the candidate’s scholarly and clinical activity.
The University of California is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability, age or protected veteran status. For the complete University of California nondiscrimination and affirmative action policy see: UC Nondiscrimination & Affirmative Action Policy
Internal Number: JPF03573
About Department of Molecular and Medical Pharmacology
The Department of Molecular and Medical Pharmacology (DMMP) is a combined basic science and clinical department. The DMMP integrates mathematics, engineering, physical, biological and medical sciences to achieve together advances that we cannot achieve individually in three overall areas: (1) understanding biology of disease, (2) developing new molecular diagnostics and (3) developing new molecular and cellular therapeutics.
The DMMP offers an opportunity for students, postdocs, medical fellows, and basic and clinical faculty to explore together the molecular and biological mechanisms that regulate cellular and organ functions to (1) identify and understand molecular errors of disease, (2) develop means to diagnose and monitor disease, and (3) develop pharmacological means to correct these errors. Within the DMMP are the preclinical Crump Institute for Molecular Imaging (CIMI) and the Ahmanson Translational Imaging Division (ATID). Within ATID, with its Nuclear Medicine and PET imaging research and clinical service, students have access to state-of-the-art science and technology to directly impact patient care.